Haleon Pakistan is expected to report weaker earnings for the second quarter of calendar year 2026, with declining sales volumes and rising input costs likely to put pressure on profitability.
According to estimates from Optimus Capital, the company’s earnings per share (EPS) is projected at PKR 12.6, representing a 3% decline from the previous quarter and a 9% year-on-year drop.
Profit after tax (PAT) is expected to come in at approximately PKR 1.5 billion.
The anticipated decline reflects a combination of weaker domestic demand, limited pricing flexibility and higher production and transportation costs.
Sales Volumes Expected To Weaken
Haleon’s net sales are projected to decline 8% year-on-year during 2QCY26.
The expected weakness is largely attributed to an estimated 3% decline in local volumes.
The company’s FMCG-focused portfolio has also not received a price increase during the period under review.
This leaves Haleon more exposed to changes in consumer demand, particularly at a time when households continue to face pressure from higher living costs.
Lack Of Price Increases Adds Pressure
Pricing has become an important earnings driver across Pakistan’s pharmaceutical sector.
Several pharmaceutical companies have benefited from price increases that helped offset higher input costs and protect margins.
Haleon, however, has not enjoyed the same benefit during the quarter because its consumer-health portfolio has remained largely price-static.
With volumes expected to decline and prices remaining unchanged, the company has limited room to absorb rising production and distribution expenses.
Gross Margin Likely To Compress
Haleon’s gross margin is expected to decline by around one percentage point sequentially to 38.2%.
Higher active pharmaceutical ingredient (API) costs are expected to be a key factor behind the pressure.
Pain-care products are particularly exposed to rising prices of relevant pharmaceutical ingredients.
Transportation costs have also increased, adding another layer of pressure to the company’s cost structure.
The combination of higher input and logistics expenses could continue to weigh on profitability if pricing remains unchanged.
Dividend Expected To Remain At PKR9 Per Share
Despite the expected decline in earnings, Optimus Capital projects a quarterly dividend of PKR9 per share.
Maintaining the dividend would indicate continued confidence in Haleon’s cash-generation capacity despite weaker quarterly profitability.
However, the expected payout also highlights the challenge facing the company: maintaining shareholder distributions while margins are under pressure from rising costs and weaker volumes.
Haleon Faces A Different Sector Environment
The broader pharmaceutical sector is expected to perform better during the period.
Optimus Capital estimates that the pharmaceutical sector could record around a 6% increase in profit after tax, supported by price increases and lower financial charges.
Haleon’s position is different because of its consumer-health and FMCG exposure.
The company’s lack of pricing gains during the quarter means it is less able to offset cost inflation through higher selling prices.
Export Challenges Add To Industry Pressure
Pakistan’s pharmaceutical industry is also facing external challenges.
Constraints along the Afghan border continue to affect export opportunities for pharmaceutical companies, limiting potential growth from regional markets.
For Haleon, however, the immediate concern appears to be domestic demand.
A combination of weaker local volumes and higher API and logistics costs could remain a challenge if regional supply-chain pressures persist.
API And Logistics Costs Remain Key Risks
Haleon’s earnings outlook remains sensitive to movements in raw material and transportation costs.
Any further increase in API prices could put additional pressure on gross margins.
Higher freight and logistics expenses could have a similar impact, particularly if the company remains unable to pass these costs on to consumers through price increases.
This makes cost management increasingly important for protecting profitability in the coming quarters.
Volume Recovery Could Be Critical
The company’s near-term performance will depend heavily on whether domestic volumes begin to recover.
A rebound in consumer demand could provide support to revenue and help improve operating leverage.
Selective pricing adjustments could also provide Haleon with greater flexibility to manage future cost increases.
Without improvement in either volumes or pricing, however, the company could continue to lag behind pharmaceutical peers benefiting from stronger pricing dynamics.
Haleon Earnings Outlook Remains Under Pressure
The projected PKR12.6 EPS for 2QCY26 highlights the difficult operating environment facing Haleon.
A projected 9% year-on-year earnings decline, an 8% fall in sales and expected gross-margin compression point to continued pressure on the company’s core operations.
The expected PKR9 dividend provides some positive news for shareholders, but sustained earnings improvement will ultimately depend on stronger volumes and better control over API and transportation costs.
For investors, the key indicators to watch in coming quarters will be domestic demand, pricing flexibility, API prices and logistics costs.